Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Marker Therapeutics, Inc.

NASDAQ: MRKR · Life Sciences · 2 alerts · CIK 1094038

Share price
$0.8286Close, Nov 16
Market cap
$13.8M
Shares outstanding
16.67MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Marker Therapeutics, Inc. filings on SEC EDGAR ↗

7:13 AM ET 8-K
Contract Win

Marker Therapeutics Wins $2.6M Contract from Food & Drug Administration

Marker Therapeutics was awarded a $2.6 million grant from the FDA's Orphan Products Clinical Trials program to advance its lead MAR-T cell therapy, MT-601, for pancreatic cancer. The non-dilutive funding will support a Phase 1 clinical study in patients with locally advanced unresectable pancreatic cancer. Marker was one of only six recipients selected from 66 applications in fiscal year 2026.

Value
$2.6M
Counterparty
Food & Drug Administration

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.